<p>摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）中的持股在第四季度增長了 1,021.1%，根據該公司最近向 SEC 的披露。該公司在此期間購買了 61,174 股後，持有 67,165 股。摩根大通在 Aerovate Therapeutics 中的持股約佔 0.23%，價值 178,000 美元，截止到最近的報告期末。</p>
<p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<p>其他對沖基金和機構投資者最近也對該公司的持股進行了調整。Corient Private Wealth LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 98,000 美元。Ieq Capital LLC 在第四季度獲得了 Aerovate Therapeutics 的新頭寸，估計價值約為 38,000 美元。Deltec Asset Management LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 514,000 美元。FNY Investment Advisers LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 198,000 美元。最後，巴克萊 PLC 在第三季度將其在 Aerovate Therapeutics 的持股提高了 310.8%。巴克萊 PLC 現在持有該公司 18,972 股，價值 39,000 美元，此前又購買了 14,354 股。</p>
<h2>Aerovate Therapeutics 股票上漲 24.8%</h2>
<p>AVTE 股票週一開盤價為 12.48 美元。Aerovate Therapeutics, Inc.的 12 個月低點為 43.75 美元，12 個月高點為 884.98 美元。該公司的 50 日移動平均線為 82.82 美元，200 日移動平均線為 86.86 美元。公司的市值為 3.6173 億美元，市盈率為-4.17，貝塔值為 0.95。</p>
<p>Aerovate Therapeutics（NASDAQ:AVTE - 獲取免費報告）最近在 4 月 25 日星期五發布了季度財報。該公司報告每股收益為（3.15 美元），超出市場共識預期的（10.50 美元）7.35 美元。分析師平均預計 Aerovate Therapeutics, Inc.在本年度將發佈-2.64 的每股收益。</p>
<h2>Aerovate Therapeutics 分紅公告</h2>
<p>該公司最近還披露了一項分紅，已於 4 月 28 日星期一支付。4 月 25 日的股東記錄將獲得 84.00 美元的分紅。除息日期為 4 月 29 日星期二。</p>
<h2>關於 Aerovate Therapeutics</h2>
<p>（免費報告）</p>
<p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>何時出售股票以獲利或止損</li>
<li>西部數據：存儲行業是否準備反彈？</li>
<li>便士股票是否適合你的投資組合？</li>
<li>Wingstop 股票因第一季度超預期和擴張前景而上漲</li>
<li>如何捕捉分紅增加的好處</li>
<li>為什麼像埃克森美孚和赫斯這樣的能源股票重新受到關注</li>
</ul>
<p><strong>想看看其他對沖基金持有的 AVTE 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
<p>在考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
<p>雖然 Aerovate Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVTE

摩根大通

<p>摩根大通（JPMorgan Chase & Co.）在 2023 年第四季度將其在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）的持股增加了 1,021.1%，目前持有 67,165 股，價值 178,000 美元。其他機構投資者也增持了該公司的股份。Aerovate 的股票上漲了 24.8%，開盤價為 12.48 美元，市值為 3.6173 億美元。該公司報告的季度每股收益為（3.15 美元），超出預期。Aerovate 專注於開發罕見心肺疾病的治療方案，並最近宣佈派發 84.00 美元的股息</p>

<p>JPMorgan Chase &amp; Co. grew its position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 1,021.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,165 shares of the company's stock after purchasing an additional 61,174 shares during the period. JPMorgan Chase &amp; Co. owned about 0.23% of Aerovate Therapeutics worth $178,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）中的持股在第四季度增長了 1,021.1%，根據該公司最近向 SEC 的披露。該公司在此期間購買了 61,174 股後，持有 67,165 股。摩根大通在 Aerovate Therapeutics 中的持股約佔 0.23%，價值 178,000 美元，截止到最近的報告期末。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in shares of Aerovate Therapeutics in the fourth quarter worth about $98,000. Ieq Capital LLC acquired a new position in shares of Aerovate Therapeutics in the 4th quarter valued at approximately $38,000. Deltec Asset Management LLC bought a new stake in Aerovate Therapeutics during the 4th quarter worth approximately $514,000. FNY Investment Advisers LLC bought a new stake in Aerovate Therapeutics during the 4th quarter worth approximately $198,000. Finally, Barclays PLC raised its holdings in Aerovate Therapeutics by 310.8% during the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock worth $39,000 after buying an additional 14,354 shares during the period.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也對該公司的持股進行了調整。Corient Private Wealth LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 98,000 美元。Ieq Capital LLC 在第四季度獲得了 Aerovate Therapeutics 的新頭寸，估計價值約為 38,000 美元。Deltec Asset Management LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 514,000 美元。FNY Investment Advisers LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約為 198,000 美元。最後，巴克萊 PLC 在第三季度將其在 Aerovate Therapeutics 的持股提高了 310.8%。巴克萊 PLC 現在持有該公司 18,972 股，價值 39,000 美元，此前又購買了 14,354 股。</p>
</div><h2>Aerovate Therapeutics Stock Up 24.8 %</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 股票上漲 24.8%</h2>
</div><p>Shares of AVTE stock opened at $12.48 on Monday. Aerovate Therapeutics, Inc. has a 12-month low of $43.75 and a 12-month high of $884.98. The firm has a fifty day moving average of $82.82 and a 200-day moving average of $86.86. The company has a market capitalization of $361.73 million, a price-to-earnings ratio of -4.17 and a beta of 0.95.</p>
<div class="lb-trans"><p>AVTE 股票週一開盤價為 12.48 美元。Aerovate Therapeutics, Inc.的 12 個月低點為 43.75 美元，12 個月高點為 884.98 美元。該公司的 50 日移動平均線為 82.82 美元，200 日移動平均線為 86.86 美元。公司的市值為 3.6173 億美元，市盈率為-4.17，貝塔值為 0.95。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $7.35. On average, equities analysts expect that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（NASDAQ:AVTE - 獲取免費報告）最近在 4 月 25 日星期五發布了季度財報。該公司報告每股收益為（3.15 美元），超出市場共識預期的（10.50 美元）7.35 美元。分析師平均預計 Aerovate Therapeutics, Inc.在本年度將發佈-2.64 的每股收益。</p>
</div><h2>Aerovate Therapeutics Dividend Announcement</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 分紅公告</h2>
</div><p>The firm also recently disclosed a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th.</p>
<div class="lb-trans"><p>該公司最近還披露了一項分紅，已於 4 月 28 日星期一支付。4 月 25 日的股東記錄將獲得 84.00 美元的分紅。除息日期為 4 月 29 日星期二。</p>
</div><h2>About Aerovate Therapeutics</h2>
<div class="lb-trans"><h2>關於 Aerovate Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Western Digital: Is the Storage Sector Set for a Rebound?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Wingstop Stock Jumps on Q1 Beat, Expansion Outlook</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Why Energy Stocks Like Exxon and Hess Are Back in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>何時出售股票以獲利或止損</li>
<li>西部數據：存儲行業是否準備反彈？</li>
<li>便士股票是否適合你的投資組合？</li>
<li>Wingstop 股票因第一季度超預期和擴張前景而上漲</li>
<li>如何捕捉分紅增加的好處</li>
<li>為什麼像埃克森美孚和赫斯這樣的能源股票重新受到關注</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AVTE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 AVTE 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aerovate Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）擁有 178,000 美元的持倉